加载中
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
前收盘价
US$21.12
+US$0.99 · +4.92%
盘中时间采用ET。市场数据可能有所延迟。
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
日内区间
当前US$21.12
52周区间
当前US$21.12
盘中时间采用ET。市场数据可能有所延迟。
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
日内区间
当前US$21.12
52周区间
当前US$21.12
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 1815.3万 USD | 1291.8万 USD | 1538万 USD | 1322.7万 USD | 954.5万 USD |
| 销售、一般及管理费用 | 942.1万 USD | 692.9万 USD | 751.7万 USD | 600.7万 USD | 334.9万 USD |
| 营业费用 | 2757.4万 USD | 1984.7万 USD | 2289.7万 USD | 1923.4万 USD | 1289.4万 USD |
| 利息收入 | 113.2万 USD | 84.7万 USD | 63.7万 USD | 14.9万 USD | 4000 USD |
| 营业利润 | −2757.4万 USD | −1984.7万 USD | −2289.7万 USD | −1923.4万 USD | −1289.4万 USD |
| 净利润 | −2644.2万 USD | −1900万 USD | −2226万 USD | −1908.5万 USD | −1289万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1478.56万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM1099.87万0.01%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF462.93万0.00%954亿 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO384.61万0.03%139.17亿 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO223.28万0.01%180亿 USD0.06%US$112.66+0.50%
Fidelity Enhanced Small Cap ETFFESM204.92万0.03%64.1亿 USD0.28%US$45.46+0.46%
Invesco Dorsey Wright SmallCap Momentum ETFDWAS168.05万0.42%3.99亿 USD0.60%US$107.24+1.40%
iShares Micro-Cap ETFIWC132.98万0.10%13.17亿 USD0.60%US$183+0.11%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMInvesco Dorsey Wright SmallCap Momentum ETFDWASiShares Micro-Cap ETFIWCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
